TY - JOUR
T1 - Core Genome Multilocus Sequence Typing and Antibiotic Susceptibility Prediction from Whole-Genome Sequence Data of Multidrug-Resistant Pseudomonas aeruginosa Isolates
AU - Cunningham, Scott A.
AU - Eberly, Allison R.
AU - Beisken, Stephan
AU - Posch, Andreas E.
AU - Schuetz, Audrey N.
AU - Patel, Robin
N1 - Funding Information:
Editor S. Wesley Long, Houston Methodist Hospital Copyright © 2022 Cunningham et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. Address correspondence to Robin Patel, [email protected]. *Present address: Allison R. Eberly, Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. The authors declare a conflict of interest. Scott A. Cunningham reports receiving an honorarium from the Antibiotic Resistance Leadership Group. Patel reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. Patel is a consultant to PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and HealthTrackRx; monies are paid to Mayo Clinic. Mayo Clinic and Patel have a relationship with Pathogenomix. Patel has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. Patel is also a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Patel receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Received 4 October 2022 Accepted 24 October 2022 Published 9 November 2022
Funding Information:
R.P. reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. R.P. is a consultant to Curetis, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and Qvella; monies are paid to Mayo Clinic. Mayo Clinic and R.P. have a relationship with Pathogenomix. R.P. has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. R.P. is also a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, R.P. has a patent on Bordetella pertussis/ parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. R.P. receives honoraria from the National Board of Medical Examiners, UpToDate, and the Infectious Diseases Board Review Course. S.A.C. reports receiving an honorarium from the Antibiotic Resistance Leadership Group.
Publisher Copyright:
© 2022 Cunningham et al.
PY - 2022/11
Y1 - 2022/11
N2 - Over the past decade, whole-genome sequencing (WGS) has overtaken traditional bacterial typing methods for studies of genetic relatedness. Further, WGS data generated during epidemiologic studies can be used in other clinically relevant bioinformatic applications, such as antibiotic resistance prediction. Using commercially available software tools, the relatedness of 38 clinical isolates of multidrug-resistant Pseudomonas aeruginosa was defined by two core genome multilocus sequence typing (cgMLST) methods, and the WGS data of each isolate was analyzed to predict antibiotic susceptibility to nine antibacterial agents. The WGS typing and resistance prediction data were compared with pulsed-field gel electrophoresis (PFGE) and phenotypic antibiotic susceptibility results, respectively. Simpson’s Diversity Index and adjusted Wallace pairwise assessments of the three typing methods showed nearly identical discriminatory power. Antibiotic resistance prediction using a trained analytical pipeline examined 342 bacterial-drug combinations with an overall categorical agreement of 92.4% and very major, major, and minor error rates of 3.6, 4.1, and 4.1%, respectively.
AB - Over the past decade, whole-genome sequencing (WGS) has overtaken traditional bacterial typing methods for studies of genetic relatedness. Further, WGS data generated during epidemiologic studies can be used in other clinically relevant bioinformatic applications, such as antibiotic resistance prediction. Using commercially available software tools, the relatedness of 38 clinical isolates of multidrug-resistant Pseudomonas aeruginosa was defined by two core genome multilocus sequence typing (cgMLST) methods, and the WGS data of each isolate was analyzed to predict antibiotic susceptibility to nine antibacterial agents. The WGS typing and resistance prediction data were compared with pulsed-field gel electrophoresis (PFGE) and phenotypic antibiotic susceptibility results, respectively. Simpson’s Diversity Index and adjusted Wallace pairwise assessments of the three typing methods showed nearly identical discriminatory power. Antibiotic resistance prediction using a trained analytical pipeline examined 342 bacterial-drug combinations with an overall categorical agreement of 92.4% and very major, major, and minor error rates of 3.6, 4.1, and 4.1%, respectively.
KW - Psuedomonas aeruginosa
KW - core genome multilocus sequence typing
KW - pulse field gel electrophoresis
KW - whole-genome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85144637102&partnerID=8YFLogxK
U2 - 10.1128/spectrum.03920-22
DO - 10.1128/spectrum.03920-22
M3 - Article
C2 - 36350158
AN - SCOPUS:85144637102
SN - 2165-0497
VL - 10
JO - Microbiology spectrum
JF - Microbiology spectrum
IS - 6
ER -